Publications by authors named "J C Beguin"

Background: Carboplatin is a human chemotherapeutic agent which is frequently used in dogs for the management of solid tumors. In human patient, its dosage is adjusted carefully, based on the creatinine clearance computation. In dogs however, the pharmacokinetics of carboplatin is poorly known and the dose 300 mg/m2 is based mostly on empirical data.

View Article and Find Full Text PDF

Background: Myeloma-related disorders (MRDs) are rare and poorly documented neoplasms of cats.

Hypothesis/objectives: To describe clinical, clinicopathologic, and imaging findings, response to treatment, and survival time and to identify factors associated with shorter outcomes in cats with MRD.

Animals: Fifty cats with a diagnosis of MRD.

View Article and Find Full Text PDF
Article Synopsis
  • This report highlights a rare case of cutaneous mast cell tumors in an 11-year-old Prim'Holstein cow who had multiple skin nodules for five months.
  • Diagnosis was confirmed through cytologic and histologic analyses, along with the detection of KIT expression in the neoplastic mast cells.
  • Although the cow showed a partial response to corticosteroids, euthanasia was chosen ultimately, with post-mortem examinations revealing no metastases in key organs.
View Article and Find Full Text PDF
Article Synopsis
  • * 57 cats were included, revealing an overall response rate of 42%, with median survival time of 131 days and a median progression-free interval of 148 days.
  • * Positive prognostic factors included achieving complete or partial response and the absence of lymph node involvement, while negative factors included gastrointestinal tract infiltration and infiltration of non-hematopoietic organs.
View Article and Find Full Text PDF

TG6002 is an oncolytic vaccinia virus expressing FCU1 protein, which converts 5-fluorocytosine into 5-fluorouracil. The study objectives were to assess tolerance, viral replication, 5-fluorouracil synthesis, and tumor microenvironment modifications to treatment in dogs with spontaneous malignant tumors. Thirteen dogs received one to three weekly intratumoral injections of TG6002 and 5-fluorocytosine.

View Article and Find Full Text PDF